CN
Drug Modalities
Technical Solutions
ESG
Newsroom
About Us
Contact Us
CN
CN
Home/Newsroom/News

News 2020-04-21

Porton Successfully Receives Third US FDA Inspection.

We are proud to announce that Porton’s cGMP-compliant Erlang site located in the Chonqing Metro Region, China passed a 4-day general inspection [April 24-28, 2016] by the US FDA without any Form 483 observations.  This is the third successful inspection of our China sites by the US FDA since 2013.  Supported by a unified Quality Management System and Corporate Quality Group, Porton’s production sites continue to reliably deliver efficient and high-quality manufacturing solutions across the full life cycle for our valued global customers.  Learn how we can help you – contact us today!
Note:  Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Others
More

News 2026-08-05

Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization

Porton Advanced Solutions Ltd. has officially been granted a Drug Manufacturing License (Class C) by the National Medical Products Administration (NMPA). This milestone qualifies Porton Advanced to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products, extending its CDMO services from process development and clinical production through to the commercialization stage.

News 2026-07-08

Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance

Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Become part of Porton's community to access personalized insights and resources.
Subscribe for the Newsletter
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.
US: (609) 860-1300
CN: (86) 23-8608-3200

ⓒ 2025 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton's community to access personalized insights and resources.
Submit
By clicking “Subscribe,” you acknowledge that you have read and agree to our Legal Disclaimer, Terms of Use, and Privacy & Cookie Policy. Porton will use the contact information you provide to communicate with you about our products, services, and other relevant updates. You may unsubscribe at any time. For more information about how we protect your privacy and manage your communication preferences, please review our Privacy & Cookie Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200